ANAS Stock Overview
Alternaturals, Inc. manufactures and distributes supplements and all-natural remedies that are alternatives to prescription drugs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Alternaturals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0042 |
| 52 Week High | US$0.017 |
| 52 Week Low | US$0.0012 |
| Beta | 0 |
| 1 Month Change | -17.24% |
| 3 Month Change | -40.00% |
| 1 Year Change | -73.75% |
| 3 Year Change | -92.18% |
| 5 Year Change | 75.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| ANAS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -17.2% | 3.0% | 0.3% |
| 1Y | -73.8% | 12.0% | 24.2% |
Return vs Industry: ANAS underperformed the US Pharmaceuticals industry which returned 12.5% over the past year.
Return vs Market: ANAS underperformed the US Market which returned 22.8% over the past year.
Price Volatility
| ANAS volatility | |
|---|---|
| ANAS Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANAS's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ANAS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | n/a | n/a | n/a |
Alternaturals, Inc. manufactures and distributes supplements and all-natural remedies that are alternatives to prescription drugs. Its products include Focamine, an all-natural focus, attention, and concentration promoter for people suffering from ADHD; and Sombium, an alternative sleep aid. The company was formerly known as Zhong Nong Yuan Fang Holdings, Inc. and changed its name to Alternaturals, Inc. in March 2022.
Alternaturals, Inc. Fundamentals Summary
| ANAS fundamental statistics | |
|---|---|
| Market cap | US$529.05k |
| Earnings (TTM) | -US$381.30k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ANAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANAS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$381.30k |
| Earnings | -US$381.30k |
Last Reported Earnings
Sep 30, 2001
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ANAS perform over the long term?
See historical performance and comparison